Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 19/20 | 0.54 |
| ▸ | JAK3 | P52333 | 19/20 | 0.54 |
| ▸ | JAK2 | O60674 | 18/20 | 0.54 |
| ▸ | TYK2 | P29597 | 18/20 | 0.54 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.48 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14697181 | 0.74 | TYMP (0.49) | JAK1JAK3JAK2TYK2 | |
| Hydrochloric Acid SCHEMBL14697453 | 0.73 | TYMP (0.47) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL20944577 | 0.70 | JAK1 (1.00) | JAK1JAK3JAK2TYK2NUAK1 | |
| SCHEMBL20944563 | 0.70 | JAK1 (1.00) | JAK1JAK3JAK2TYK2NUAK1 | |
| SCHEMBL20944727 | 0.70 | JAK1 (1.00) | JAK1JAK3JAK2TYK2NUAK1 | |
| SCHEMBL13075337 | 0.70 | CYP1A1 (0.39) | — | |
| SCHEMBL20944674 | 0.69 | JAK2 (1.00) | JAK1JAK3JAK2TYK2NUAK1 | |
| SCHEMBL20944732 | 0.69 | JAK2 (1.00) | JAK1JAK3JAK2TYK2NUAK1 | |
| SCHEMBL20944621 | 0.69 | JAK1 (1.00) | JAK1JAK3JAK2TYK2NUAK1 | |
| SCHEMBL20944556 | 0.69 | JAK1 (0.84) | JAK1JAK3JAK2TYK2NUAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399979-B2 | Janus kinase inhibitors and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190127377-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127377-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | JAK2, JAK1, JAK3 | JAK1 2/4885JAK3 3/4885JAK2 1/4885 |
| US-10399979-B2 | Janus kinase inhibitors and uses thereof | JAK2, JAK1, JAK3 | JAK1 2/4885JAK3 3/4885JAK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.